SER
Serina Therapeutics, Inc. · Healthcare
Insiders bought $37K of Serina Therapeutics, Inc. in the last 12 months
1 insider bought on 1 day.
SER over the last year
Largest buyers, last 12 months
SER after insider buys
3 months after each buy, from the first price a copier could get.
8 buys since 2024 with 3 months of prices.
Every filing
10 insider filings since 2024, newest first
Karen J Wilson · Director
Randall Moreadith · Chief Scientific Officer
Randall Moreadith · Chief Scientific Officer
Gregory Bailey · Director
Steven Mintz · Director
Steven Mintz · Director
Gregory Bailey · Director
Gregory Bailey · Director
Gregory Bailey · Director
Steven Mintz · Director
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.